Mª Alejandra Asensio Ruiz Bücher

The book discusses the modification of the licensed indication for Radium-223 dichloride, an alpha particle-emitting radiopharmaceutical used in treating castration-resistant prostate cancer with bone metastases. Following the emergence of drug-drug interactions with commonly used medications like abiraterone and prednisone, its use has been limited to monotherapy or in combination with luteinizing hormone-releasing hormone analogues. This change has positioned Ra-223 as a third-line treatment, raising concerns regarding its effectiveness and safety in this new treatment context.

El Dicloruro de Radio-223 es un radiofármaco para el tratamiento de cáncer de próstata resistente a castración con metástasis óseas. Desde junio de 2018, su uso se restringió a monoterapia o con análogos de la hormona liberadora de hormona luteinizante, convirtiéndose en tratamiento de tercera línea, con evidencia limitada sobre su efectividad y seguridad.